LB Pharmaceuticals Inc LBRX
Set alert
40.85 USD +1.81 +4.64%
As of Nov 3, 11:27 AM ET
39.15 Day range 41.40
14.32 52-week range 50.16
- YTD
- +83.51%
- 1 year
- +152.63%
- Open
- 39.65
- Prev close
- 39.04
- Mkt cap
- 1.32B
- Vol
- 47.34K
- Avg vol
- 361.92K
- EPS
- 0.10
- P/E
- 408.50
- Div yield
- 0.00%
More statistics
- Low
- 39.15
- High
- 41.40
- Forward P/E
- -7.26
- Beta
- 0.00
- Short ratio
- 12.64
- Inst. own
- 102.44%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 41.38
- 200-d avg
- 32.57
- 1y target
- 58.00
5D chart
Signals (129)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Nov 3, 11:05 AM | 23 minutes ago |
| MACD: Sell Signal | Nov 3, 10:50 AM | 38 minutes ago |
| SMA: Bearish | Nov 3, 10:45 AM | 43 minutes ago |
| SMA: Bullish | Nov 3, 10:35 AM | 53 minutes ago |
| SMA: Bearish | Nov 3, 10:25 AM | 1 hour ago |
| RSI: Overbought | Nov 3, 9:45 AM | 1 hour ago |
| SMA: Bullish | Nov 3, 9:30 AM | 1 hour ago |
| SMA: Bullish | Nov 3, 9:30 AM | 1 hour ago |
| MACD: Buy Signal | Nov 3, 9:30 AM | 1 hour ago |
| SMA: Bearish | Nov 2, 3:45 PM | 19 hours ago |
| SMA: Bullish | Nov 2, 3:40 PM | 19 hours ago |
| SMA: Bearish | Nov 2, 3:30 PM | 19 hours ago |
| MACD: Sell Signal | Nov 2, 3:30 PM | 19 hours ago |
| MACD: Buy Signal | Nov 2, 2:50 PM | 20 hours ago |
| SMA: Bullish | Nov 2, 2:45 PM | 20 hours ago |
| SMA: Bullish | Nov 2, 2:45 PM | 20 hours ago |
| SMA: Bearish | Nov 2, 2:20 PM | 21 hours ago |
| SMA: Bearish | Nov 2, 2:20 PM | 21 hours ago |
| MACD: Sell Signal | Nov 2, 2:20 PM | 21 hours ago |
| SMA: Bullish | Nov 2, 1:55 PM | 21 hours ago |
Newest 20 of 129.
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 58.00 +42.0% upside
Now 40.85
- Target (low)
- 35.00
- Target (mean)
- 58.00
- Target (high)
- 80.00
Ratings (0m) 11 10 buy · 1 hold · 0 sell
- Strong buy2
- Buy8
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 11
- 1 month ago 8
- 2 months ago 8
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -1.52 | -1.74 – -1.07 | -0.61 | -149.2% | 0 | 0.0% | 8 |
| Next quarter | -1.52 | -1.81 – -1.15 | -0.45 | -238.3% | 0 | 0.0% | 8 |
| Current year | -5.47 | -5.93 – -4.63 | -3.13 | -74.9% | 0 | 0.0% | 9 |
| Next year | -5.13 | -6.41 – -4.14 | -5.47 | +6.3% | 0 | 0.0% | 9 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 9, 2026 | Canaccord Genuity | Initiated | — | Buy |
| Oct 6, 2026 | Guggenheim | Initiated | — | Buy |
| Oct 5, 2026 | Roth Capital | Downgrade | Buy | Neutral |
| Oct 2, 2026 | Needham | Initiated | — | Buy |
| Aug 24, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 12, 2026 | BMO Capital | Maintained | Outperform | Outperform |
| Aug 3, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jul 21, 2026 | BMO Capital | Initiated | — | Outperform |
| Jul 7, 2026 | Wolfe Research | Initiated | — | Outperform |
| Apr 27, 2026 | HC Wainwright & Co. | Initiated | — | Buy |
| Apr 10, 2026 | Craig-Hallum | Initiated | — | Buy |
| Mar 27, 2026 | Stifel | Maintained | Buy | Buy |
| Dec 11, 2025 | Stifel | Maintained | Buy | Buy |
| Oct 6, 2025 | Stifel | Initiated | — | Buy |
| Oct 6, 2025 | Piper Sandler | Initiated | — | Overweight |
| Oct 6, 2025 | Leerink Partners | Initiated | — | Outperform |